{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:41:23Z","timestamp":1791996083269,"version":"4.4.0"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T00:00:00Z","timestamp":1594771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Association of Physicians of MUHC"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,5,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Bloodstream infections (BSIs) with methicillin-susceptible Staphylococcus aureus (MSSA) are associated with significant morbidity and mortality. Our objective in this study was to determine the efficacy of synergistic treatment with daptomycin when given with either cefazolin or cloxacillin for the treatment of MSSA BSI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A randomized, double-blind, placebo-controlled trial was performed at 2 academic hospitals in Montreal, Canada. Patients\u2005aged \u226518 years with MSSA BSI receiving either cefazolin or cloxacillin monotherapy were considered for inclusion. In addition to the standard-of-care treatment, participants received a 5-day course of adjunctive daptomycin or placebo. The primary outcome was the duration of MSSA BSI in days.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 318 participants screened, 115 were enrolled and 104 were included in the intention-to-treat analysis (median age, 67 years; 34.5% female). The median duration of bacteremia was 2.04 days among patients who received daptomycin vs 1.65 days in those who received placebo (absolute difference, 0.39 days; P\u2005=\u2005.40). In a modified intention-to-treat analysis that involved participants who remained bacteremic at the time of enrollment, we found a median duration of bacteremia of 3.06 days among patients who received daptomycin vs 3.0 days in those who received placebo (absolute difference, 0.06 days; P\u2005=\u2005.77). Ninety-day mortality in the daptomycin arm was 18.9% vs 17.7% in the placebo arm (P\u2005=\u20051.0).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Among patients with MSSA BSIs, the administration of adjunctive daptomycin therapy to standard-of-care treatment did not shorten the duration of bacteremia and should not be routinely considered.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trials Registration<\/jats:title>\n                    <jats:p>NCT02972983.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciaa1000","type":"journal-article","created":{"date-parts":[[2020,7,12]],"date-time":"2020-07-12T07:07:03Z","timestamp":1594537623000},"page":"e196-e203","source":"Crossref","is-referenced-by-count":52,"title":["Adjunctive Daptomycin in the Treatment of Methicillin-susceptible\n                    <i>Staphylococcus aureus<\/i>\n                    Bacteremia: A Randomized, Controlled Trial"],"prefix":"10.1093","volume":"72","author":[{"given":"Matthew P","family":"Cheng","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7948-3161","authenticated-orcid":false,"given":"Alexander","family":"Lawandi","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, McGill University, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5388-0396","authenticated-orcid":false,"given":"Guillaume","family":"Butler-Laporte","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, McGill University, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"De l\u2019\u00c9toile-Morel","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, McGill University, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katryn","family":"Paquette","sequence":"additional","affiliation":[{"name":"Division of Neonatology, Montreal Children\u2019s Hospital, McGill University, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd C","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, McGill University, Montreal, Quebec, Canada"},{"name":"Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada"},{"name":"Clinical Practice Assessment Unit, Department of Medicine, McGill University, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,7,15]]},"reference":[{"key":"2021050500463530000_CIT0001","doi-asserted-by":"crossref","first-page":"547","DOI":"10.7326\/M19-1696","article-title":"Blood culture results before and after antimicrobial administration in patients with severe manifestations of sepsis: a diagnostic study","volume":"171","author":"Cheng","year":"2019","journal-title":"Ann Intern Med"},{"key":"2021050500463530000_CIT0002","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1001\/archinte.163.17.2066","article-title":"Clinical identifiers of complicated Staphylococcus aureus bacteremia","volume":"163","author":"Fowler","year":"2003","journal-title":"Arch Intern Med"},{"key":"2021050500463530000_CIT0003","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s15010-019-01330-5","article-title":"Epidemiology and outcome determinants of Staphylococcus aureus bacteremia revisited: a population-based study","volume":"47","author":"Lam","year":"2019","journal-title":"Infection"},{"key":"2021050500463530000_CIT0004","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/MAJ.0000000000000350","article-title":"Predictive factors for metastatic infection in patients with bacteremia caused by methicillin-sensitive Staphylococcus aureus","volume":"349","author":"Horino","year":"2015","journal-title":"Am J Med Sci"},{"key":"2021050500463530000_CIT0005","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1128\/CMR.05022-11","article-title":"Predictors of mortality in Staphylococcus aureus bacteremia","volume":"25","author":"van Hal","year":"2012","journal-title":"Clin Microbiol Rev"},{"key":"2021050500463530000_CIT0006","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s10096-016-2598-8","article-title":"Risk factors for long-term mortality of Staphylococcus aureus bacteremia","volume":"35","author":"Yahav","year":"2016","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2021050500463530000_CIT0007","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1086\/589717","article-title":"Staphylococcus aureus bloodstream infections: risk factors, outcomes, and the influence of methicillin resistance in Calgary, Canada, 2000\u20132006","volume":"198","author":"Laupland","year":"2008","journal-title":"J Infect Dis"},{"key":"2021050500463530000_CIT0008","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1093\/cid\/civ120","article-title":"Impact of infectious disease consultation on quality of care, mortality, and length of stay in Staphylococcus aureus bacteremia: results from a large multicenter cohort study","volume":"60","author":"Bai","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2021050500463530000_CIT0009","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1001\/jama.2018.13155","article-title":"Effect of algorithm-based therapy vs usual care on clinical success and serious adverse events in patients with staphylococcal bacteremia: a randomized clinical trial","volume":"320","author":"Holland","year":"2018","journal-title":"JAMA"},{"key":"2021050500463530000_CIT0010","doi-asserted-by":"crossref","first-page":"214","DOI":"10.15585\/mmwr.mm6809e1","article-title":"Vital signs: epidemiology and recent trends in methicillin-resistant and in methicillin-susceptible Staphylococcus aureus bloodstream infections\u2014United States","volume":"68","author":"Kourtis","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2021050500463530000_CIT0011","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/cid\/civ808","article-title":"Combination of vancomycin and beta-lactam therapy for methicillin-resistant Staphylococcus aureus bacteremia: a pilot multicenter randomized controlled trial","volume":"62","author":"Davis","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2021050500463530000_CIT0012","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/S0140-6736(17)32456-X","article-title":"Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"391","author":"Thwaites","year":"2018","journal-title":"Lancet"},{"key":"2021050500463530000_CIT0013","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s13063-016-1295-3","article-title":"CAMERA2\u2014combination antibiotic therapy for methicillin-resistant Staphylococcus aureus infection: study protocol for a randomised controlled trial","volume":"17","author":"Tong","year":"2016","journal-title":"Trials"},{"key":"2021050500463530000_CIT0014","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1469-0691.2006.01589.x","article-title":"Increasing incidence but decreasing in-hospital mortality of adult Staphylococcus aureus bacteraemia between 1981 and 2000","volume":"13","author":"Benfield","year":"2007","journal-title":"Clin Microbiol Infect"},{"key":"2021050500463530000_CIT0015","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/j.amjmed.2016.01.048","article-title":"Back to the future: penicillin-susceptible Staphylococcus aureus","volume":"129","author":"Cheng","year":"2016","journal-title":"Am J Med"},{"key":"2021050500463530000_CIT0016","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1444-0903.2001.00029.x","article-title":"Prospective study of 424 cases of Staphylococcus aureus bacteraemia: determination of factors affecting incidence and mortality","volume":"31","author":"Hill","year":"2001","journal-title":"Intern Med J"},{"key":"2021050500463530000_CIT0017","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1186\/1471-2334-12-260","article-title":"Stable incidence and continued improvement in short term mortality of Staphylococcus aureus bacteraemia between 1995 and 2008","volume":"12","author":"Mejer","year":"2012","journal-title":"BMC Infect Dis"},{"key":"2021050500463530000_CIT0018","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1055\/s-0034-1396906","article-title":"Combination antibiotic treatment of serious methicillin-resistant Staphylococcus aureus infections","volume":"36","author":"Davis","year":"2015","journal-title":"Semin Respir Crit Care Med"},{"key":"2021050500463530000_CIT0019","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/cid\/cix287","article-title":"Comparative effectiveness of cefazolin versus nafcillin or oxacillin for treatment of methicillin-susceptible Staphylococcus aureus infections complicated by bacteremia: a nationwide cohort study","volume":"65","author":"McDanel","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2021050500463530000_CIT0020","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.cmi.2019.03.010","article-title":"Cefazolin versus anti-staphylococcal penicillins for the treatment of patients with Staphylococcus aureus bacteraemia","volume":"25","author":"Weis","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"2021050500463530000_CIT0021","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa053783","article-title":"Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus","volume":"355","author":"Fowler","year":"2006","journal-title":"N Engl J Med"},{"key":"2021050500463530000_CIT0022","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/jac\/dkh546","article-title":"Daptomycin: a lipopeptide antibiotic for the treatment of serious gram-positive infections","volume":"55","author":"Steenbergen","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"2021050500463530000_CIT0023","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.bbamem.2006.02.009","article-title":"Mode of action of the new antibiotic for gram-positive pathogens daptomycin: comparison with cationic antimicrobial peptides and lipopeptides","volume":"1758","author":"Straus","year":"2006","journal-title":"Biochim Biophys Acta"},{"key":"2021050500463530000_CIT0024","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1128\/AAC.48.8.2871-2875.2004","article-title":"Synergy of daptomycin with oxacillin and other beta-lactams against methicillin-resistant Staphylococcus aureus","volume":"48","author":"Rand","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"2021050500463530000_CIT0025","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1179\/joc.2005.17.6.614","article-title":"Evaluation of in vitro interaction of daptomycin with gentamicin or beta-lactam antibiotics against Staphylococcus aureus and enterococci by FIC index and timed-kill curves","volume":"17","author":"Snydman","year":"2005","journal-title":"J Chemother"},{"key":"2021050500463530000_CIT0026","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1093\/infdis\/jiv512","article-title":"Reversion from methicillin susceptibility to methicillin resistance in Staphylococcus aureus during treatment of bacteremia","volume":"213","author":"Proulx","year":"2016","journal-title":"J Infect Dis"},{"key":"2021050500463530000_CIT0027","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1093\/cid\/ciz018","article-title":"Impact of beta-lactam and daptomycin combination therapy on clinical outcomes in methicillin-susceptible Staphylococcus aureus bacteremia: a propensity score-matched analysis","volume":"69","author":"Grillo","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2021050500463530000_CIT0028","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1186\/s13063-018-2668-6","article-title":"Daptomycin versus placebo as an adjunct to beta-lactam therapy in the treatment of Staphylococcus aureus bacteremia: study protocol for a randomized controlled trial","volume":"19","author":"Cheng","year":"2018","journal-title":"Trials"},{"key":"2021050500463530000_CIT0029","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1001\/jama.285.15.1987","article-title":"The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials","volume":"285","author":"Moher","year":"2001","journal-title":"JAMA"},{"key":"2021050500463530000_CIT0030","volume-title":"Cumitech 1C, blood cultures IV. Coordinating","author":"Baron","year":"2005"},{"key":"2021050500463530000_CIT0031","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1001\/jama.2014.9743","article-title":"Clinical management of Staphylococcus aureus bacteremia: a review","volume":"312","author":"Holland","year":"2014","journal-title":"JAMA"},{"key":"2021050500463530000_CIT0032","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2021050500463530000_CIT0033","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.cmi.2016.10.023","article-title":"Proposed primary endpoints for use in clinical trials that compare treatment options for bloodstream infection in adults: a consensus definition","volume":"23","author":"Harris","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"2021050500463530000_CIT0034","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1001\/jama.2020.0103","article-title":"Effect of vancomycin or daptomycin with vs without an antistaphylococcal \u03b2-lactam on mortality, bacteremia, relapse, or treatment failure in patients with MRSA bacteremia: a randomized clinical trial","volume":"323","author":"Tong","year":"2020","journal-title":"JAMA"},{"key":"2021050500463530000_CIT0035","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1086\/506568","article-title":"Management of persistent bacteremia caused by methicillin-resistant Staphylococcus aureus: a survey of infectious diseases consultants","volume":"43","author":"Hageman","year":"2006","journal-title":"Clin Infect Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciaa1000\/36626504\/ciaa1000.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/72\/9\/e196\/37795384\/ciaa1000.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/72\/9\/e196\/37795384\/ciaa1000.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T20:47:13Z","timestamp":1620161233000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/72\/9\/e196\/5871967"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,15]]},"references-count":35,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,7,15]]},"published-print":{"date-parts":[[2021,5,4]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaa1000","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.738333812.793587621","asserted-by":"object"}]},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,5,1]]},"published":{"date-parts":[[2020,7,15]]}}}